No Data
Behind the Hong Kong stock CXO's sideways oscillation, foreign investors continue to sell while domestic investors accelerate their entrance.
Recently, the public fund medical hold positions data for Q3 2024 has been gradually disclosed, with a noticeable increase in CXO positions. Additionally, the Hong Kong Stock Connect funds have significantly bought CXO symbol stocks in the past 60 days, reflecting the current optimistic attitude of domestic funds towards the subsequent rebound of the CXO sector.
The bullish market stimulated the Hong Kong stock pharmaceutical sector, with Laikai Pharmaceutical soaring nearly 20%.
Statistics from the Capital Research Department of Silver (Hong Kong) show that the number of innovative drugs IND and NDA has returned to growth after hitting a low in 2022. In the third quarter of this year, 1033 drug clinical approvals were granted, a 25% year-on-year increase, with a total of 8 first-class innovative drugs approved for marketing, doubling year-on-year.
Genscript bio (01548) issued 4.18 million shares due to the exercise of options.
Genscript Bio (01548) announced that the company, on November 18, 2024, in accordance with the 2015...
Genscript Biotech Enters Sub-License Contract for Anti-PD-1 Single Domain Antibodies
Genscript bio (01548.HK): Nanjing Pengbo has reached a licensing agreement with Lixin Pharmaceutical Technology Co., Ltd.
Gelonghui November 15th | Genscript Bio (01548.HK) announced that on November 12, 2024, its non-wholly owned subsidiary, Nanjing Prosper Bio Technology Co., Ltd. ("Nanjing Prosper"),entered into a restated and amended licensing agreement with LiXin Pharmaceutical Technology Limited ("LiXin"). Under the agreement, Nanjing Prosper agreed to grant LiXin an exclusive global transferable license, and the right to grant sublicenses, enabling it to develop, produce, commercialize, and
Genscript bio (01548.HK): John Anthony Quelch has been appointed as an independent non-executive director.
On November 15, Gelonghui reported that genscript bio (01548.HK) announced that John Anthony Quelch has been appointed as an independent non-executive director and a member of the global strategy committee, effective November 14, 2024.
No Data
No Data